Boston Scientific Corporation (BSX) on Decifer

Decifer ranks BSX number 215 of 270 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 20% a year, profits grew 56% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And its own insiders have been buying.
• Revenue growing about 20% and profits up 56% are blocked by price momentum of 0 out of 35 and no stated reason to grow.

The current read

The evidence on BSX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Robotic & Minimally-Invasive Intervention: Clinical and economic evidence favoring minimally invasive robotic and thrombectomy procedures is shifting procedure volumes and capital equipment budgets toward advanced interventional platforms.

Read the full BSX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.